Ratings by Raymond James (Timur Ivannikov)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
5/5/2023 Rocket Pharmaceuticals RCKT Maintain Outperform
(N/A)
 
 
  Details
5/5/2023 Kymera Therapeutics KYMR Upgrade Outperform
(Market Perform)
30.90
(98.25)
217.96% Details
3/7/2023 Gossamer Bio Inc. GOSS Downgrade Market Perform
(Outperform)
1.83
(0.17)
-90.71% Details
1/6/2023 AnaptysBio ANAB Downgrade Market Perform
(Outperform)
29.19
(59.43)
103.6% Details
11/17/2022 Gossamer Bio Inc. GOSS Maintain Outperform
(N/A)
 
 
  Details
11/15/2022 NexImmune Inc NEXI Downgrade Market Perform
(Outperform)
0.49
(3.93)
702.04% Details
11/11/2022 Leap Therapeutics LPTX Maintain Outperform
(N/A)
 
 
  Details
11/9/2022 AnaptysBio ANAB Maintain Outperform
(N/A)
 
 
  Details
11/8/2022 Kymera Therapeutics KYMR New Coverage Market Perform
(N/A)
29.04
(98.25)
238.33% Details
9/1/2022 AnaptysBio ANAB New Coverage Outperform
(N/A)
23.76
(59.43)
150.13% Details
8/16/2022 NexImmune Inc NEXI Maintain Outperform
(N/A)
 
 
  Details
8/9/2022 Rocket Pharmaceuticals RCKT Maintain Outperform
(N/A)
 
 
  Details
7/13/2022 Leap Therapeutics LPTX Maintain Outperform
(N/A)
 
 
  Details
7/8/2022 Rocket Pharmaceuticals RCKT New Coverage Outperform
(N/A)
16.15
(3.47)
-78.51% Details
4/18/2022 Gossamer Bio KOSS New Coverage Outperform
(N/A)
7.46
(3.98)
-46.65% Details
11/15/2021 NexImmune Inc NEXI Maintain Outperform
(N/A)
 
 
  Details
11/12/2021 Catalyst Biosciences CBIO Downgrade Market Perform
(Outperform)
2.94
(17.50)
495.24% Details
9/13/2021 Leap Therapeutics LPTX Maintain Outperform
(N/A)
 
 
  Details
3/31/2021 NexImmune Inc NEXI New Coverage Outperform
(N/A)
18.32
(3.93)
-78.55% Details